Johnson & Johnson Submits Application to the European Medicines Agency Seeking Approval of a New Indication for Imbruvica in Adult Patients With Previously Untreated Mantle Cell Lymphoma Who are Eligible for Autologous Stem Cell Transplant
December 19, 2024
December 19, 2024
NEW BRUNSWICK, New Jersey, Dec. 19 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months fixed-duration ibrutinib therapy/1
Both ibrutinib-based regimens, transplant-free and with transplant, delivered clinically meaningful improvement in effi . . .
* * *
The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months fixed-duration ibrutinib therapy/1
Both ibrutinib-based regimens, transplant-free and with transplant, delivered clinically meaningful improvement in effi . . .